How Our Approach Works
The TB16-8 proprietary lead compound that will address this problem is a dual TRPV4 and TRPA1 ion channel inhibitor, thus it will prevent excess calcium influx into skin-innervating nerve fibers when the small molecule binds to the TRPV4 and TRPA1 channels.
Importantly, we are proposing to deliver our lead compound topically to the patients’ skin.
We intend to have the patient prepare before chemotherapy by applying our compound topically to skin to inhibit TRPV4 and TRPA1 in a preventative manner, thus accomplishing the key goal of neuroprotection by preventing toxic calcium overload of the pain-sensing sensory nerve cells and their nerve endings in the skin.
Our proposed to-skin topical treatment is continued as chemotherapy is initiated. TB16-8 topical treatment is then carried on throughout chemotherapy, thus maximizing a patient’s odds to end the chemotherapy on schedule by minimizing pain and irritation, securing: